Pfizer is an American pharmaceutical company founded in 1849. It is best known for developing popular drugs like Lipitor, the best-selling drug of all time for lowering cholesterol. Lipitor's active ingredient, atorvastatin, was invented in 1985 by Bruce Roth and works by inhibiting cholesterol production in the liver. It proved more effective at reducing LDL cholesterol than previous statins, contributing to Pfizer's success. Ian Read currently serves as Pfizer's Chairman and CEO.
The document discusses marketing strategies for branded and generic antibiotics, focusing on Clamoxyl, an amoxicillin antibiotic. It summarizes that Clamoxyl was initially very successful due to heavy promotion, but faced increased competition from generic amoxicillin and combination antibiotics like Augmentin over time. Government regulation in France aimed to reduce drug costs by encouraging generic substitution, which contributed to Clamoxyl's declining market share in the late 1990s. The document provides historical context on antibiotic development and details marketing approaches across the pharmaceutical industry in France.
This document provides a brand plan for PRO PL, a nutritional supplement brand, from 2018-2020. It outlines the target customer as pregnant women and women of childbearing age. The brand aims to provide overall nourishment to mothers and fetuses. Key insights indicate issues like pregnancy induced hypertension affect many pregnancies annually in India. The document reviews the nutritional supplements market and competitors. PRO PL is currently the second ranked brand in its niche segment. The brand vision is to become the most prescribed brand in its category, with an objective to reach 100 crore rupees in sales by 2020.
This document provides an overview and marketing plan for the launch of the new PPI drug Esomeprazole. The summary is:
1) Esomeprazole is aiming to target the large and growing PPI drug market by positioning itself as the most advanced PPI with higher bioavailability and safety.
2) The marketing plan includes pre-launch market research, targeting physicians and pharmacists with differentiated positioning messages emphasizing Esomeprazole as the "first choice" PPI.
3) Tactics will include sequential physician visits, message-related promotions, and a focus on tenders, competitions management, and direct-to-customer and consumer campaigns. The goal is to achieve the
Johnson & Johnson Pharmaceutical Business ReviewDeepa K
The document is an agenda for an investor presentation. It outlines the schedule for the day which includes presentations on the company's enterprise overview, pharmaceutical commercial and R&D strategies, and various therapeutic areas. It also includes notices about forward-looking statements and new molecular entities being discussed. The speakers and locations are listed next to each topic.
Olmesartan medoxomil is an angiotensin II receptor antagonist which is used for the treatment of high blood pressure. An ester prodrug, it is completely and rapidly hydrolyzed to the active acid form. It is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents
The document discusses marketing strategies for branded and generic antibiotics, focusing on Clamoxyl, an amoxicillin antibiotic. It summarizes that Clamoxyl was initially very successful due to heavy promotion, but faced increased competition from generic amoxicillin and combination antibiotics like Augmentin over time. Government regulation in France aimed to reduce drug costs by encouraging generic substitution, which contributed to Clamoxyl's declining market share in the late 1990s. The document provides historical context on antibiotic development and details marketing approaches across the pharmaceutical industry in France.
This document provides a brand plan for PRO PL, a nutritional supplement brand, from 2018-2020. It outlines the target customer as pregnant women and women of childbearing age. The brand aims to provide overall nourishment to mothers and fetuses. Key insights indicate issues like pregnancy induced hypertension affect many pregnancies annually in India. The document reviews the nutritional supplements market and competitors. PRO PL is currently the second ranked brand in its niche segment. The brand vision is to become the most prescribed brand in its category, with an objective to reach 100 crore rupees in sales by 2020.
This document provides an overview and marketing plan for the launch of the new PPI drug Esomeprazole. The summary is:
1) Esomeprazole is aiming to target the large and growing PPI drug market by positioning itself as the most advanced PPI with higher bioavailability and safety.
2) The marketing plan includes pre-launch market research, targeting physicians and pharmacists with differentiated positioning messages emphasizing Esomeprazole as the "first choice" PPI.
3) Tactics will include sequential physician visits, message-related promotions, and a focus on tenders, competitions management, and direct-to-customer and consumer campaigns. The goal is to achieve the
Johnson & Johnson Pharmaceutical Business ReviewDeepa K
The document is an agenda for an investor presentation. It outlines the schedule for the day which includes presentations on the company's enterprise overview, pharmaceutical commercial and R&D strategies, and various therapeutic areas. It also includes notices about forward-looking statements and new molecular entities being discussed. The speakers and locations are listed next to each topic.
Olmesartan medoxomil is an angiotensin II receptor antagonist which is used for the treatment of high blood pressure. An ester prodrug, it is completely and rapidly hydrolyzed to the active acid form. It is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents
Lupin launches generic hypertension drug Olmesartan Medoxomil tablets in the US market. Olmesartan is an angiotensin receptor blocker used to treat high blood pressure. It works by relaxing blood vessels to allow blood to flow more easily. Lupin received FDA approval to launch generic versions of Daiichi Sankyo's branded hypertension drug Benicar, which had US sales of $681 million in July 2017. The key safety issues reported for Olmesartan are headache, influenza-like symptoms, and dizziness.
- The document provides sales forecasts for Esoz 20, an esomeprazole magnesium tablet, for the first year in quarterly projections. It estimates sales of Rs. 2.5 crore for the year with sales increasing each month and quarter as penetration increases.
- A promotional budget of Rs. 30 lakh is allocated equally across the 4 quarters to market the brand to gastroenterologists, general physicians, surgeons and gynaecologists in metro and class 1/2 cities.
- Key activities include product sampling, branding materials, and print advertisements. Pricing is set at Rs. 15.93 per tablet with a company margin of 60% after trade discounts.
This document outlines a 10 step marketing plan for Aforvir, an affordable antihistamine medication for children. The target market is physicians who treat allergies in children aged 6 months to 5 years. Aforvir will position itself as effective, affordable, and pleasant tasting compared to competitors. Key elements of the marketing plan include an emotional promotional campaign centered on reuniting children with pets, competitive pricing, and regular physician representative visits to promote Aforvir. The overall antihistamine market is valued at $116 million growing at 16% annually, and the goal is for Aforvir to gain a larger share through this marketing strategy.
Introduction to one of best medicine company Glaxo-smith-kline commonly known as GSK. this presentation gives detail introduction about GSK functions and products. Also global strategies which company is using.
This document discusses marketing strategies for the proton pump inhibitor brand Esotid in Bangladesh. It notes that Esotid contains the molecule Esomeprazole, which has greater bioavailability than other PPIs and can maintain intragastric pH above 4 for over 17 hours. The document encourages promoting Esotid for gastroesophageal reflux disease (GERD) and gastroesophageal reflux-induced chronic cough (GERC), highlighting clinical trial results showing Esomeprazole's superiority to Omeprazole for recovering GERC patients. Promotional materials and messaging are provided to establish Esotid injection in hospitals and inform doctors of Esotid's benefits over other PPI brands for NSAID-
This document discusses strategies for launching new pharmaceutical brands. It outlines that successful product launching depends on coordination across functions. The purpose is to build sales. A launching strategy consists of marketing decisions, activities, and product attributes to present the product to its target market. The objectives are to generate income. Key aspects of launching strategy include being first to market, a first follower, or delayed entrant. Marketing decisions include market entry strategy, product positioning, and marketing mix. Strategic decisions involve company strategy, product strategy, market strategy, and competitive strategy. Tactical decisions involve the marketing mix of product, price, promotion, and distribution. Success depends on customer performance, financial performance, and technical performance. The document provides details on various strategic
Business plan of diclofenac & amoxiclavPallavi Rane
Company X plans to market Diclofenac Potassium and Amoxiclav drugs in Maharashtra and Gujarat. They will have a head office in Mumbai and employ 80 medical representatives to market the drugs. Diclofenac is used for pain and inflammation while Amoxiclav is an antibiotic. The company expects to generate Rs. 72 crore in profits in the first year from drug sales, despite expenses of Rs. 66.54 crore which include salaries, marketing costs, and incentives for medical representatives and doctors.
Nimalox is a non steroidal anti inflammatory drug with
analgesic and antipyretic properties and cox-2
selective inhibition
it's a study to re-branding Nimalox
MBA Cairo University
This document discusses special considerations for drug use in children, the elderly, and patients with hepatic or renal diseases.
In children, drug absorption, distribution, metabolism and elimination can be affected. Formulas like Young's and Clark's are used to calculate appropriate pediatric doses. The elderly have altered pharmacokinetics including slower absorption, lower protein binding, and decreased liver and kidney function. They are also more prone to drug interactions and adverse reactions. Hepatic disease can impact drug metabolism and protein synthesis, requiring dose adjustments. Renal disease reduces drug clearance, increases toxicity risk of nephrotoxic drugs, and may require modified maintenance doses based on creatinine clearance. Special monitoring is needed for safe drug use in these patient
This document discusses strategies for launching new products. It covers several key points:
1. Successful product launching depends on coordination across functions and preparation.
2. Strategic decisions for launching include identifying customers, product positioning, and developing an appropriate marketing mix.
3. Tactical decisions involve the "4 Ps" of marketing - product, price, place (distribution), and promotion.
4. The document provides an overview of different product life cycle stages and strategies for each stage.
Brand plan for 2010 glycomet (us vitamin) - mitesh shahMitesh Shah
The document provides a brand plan for Glycomet, a diabetes medication, for the year 2010. It was prepared by Mitesh Shah and submitted to Mr. Pratim Vora. The plan outlines sales objectives to increase annual unit sales and revenue. It discusses strategies and tactics to achieve these objectives, including effective promotional activities, product design, pricing, and a situational analysis. It also includes a SWOT analysis and details on hiring and training sales personnel to support the outlined goals.
This document outlines the business plan for Losartan Potassium (LOSART) for 2015. It summarizes that hypertension prevalence in Bangladesh is approximately 20% according to different sources. The cardiovascular drug market is valued at 988 crores with antihypertensives comprising 636 crores. LOSART has a 29.24% share of the antihypertensive market as the second most prescribed generic. The plan identifies opportunities to increase market share by focusing on specialty physicians and improving performance in metro areas. Objectives for 2015 include achieving 10% growth, a 4.9% market share, and reaching the number 3 market position.
This document outlines a 10 step marketing plan for Zykast, a new antihistamine/antiallergic drug intended for doctors treating patients over 15 with allergy and asthma symptoms. The plan targets these doctors and analyzes the market, competitors, promotional strategies, and positioning of Zykast to fulfill an unmet need for an affordable, effective treatment with minimal side effects. Key competitors and differentiators are identified. The overall market is estimated at $11.9 billion growing 3% annually.
This document discusses drug use during pregnancy and lactation. It notes that drug use requires special consideration as it affects both the mother and child. Many pregnant or lactating women take drugs for acute or chronic conditions. The document provides details on common drug classes used in pregnancy, considerations for drug safety and effects during each trimester, placental drug transfer, effects of pregnancy on pharmacokinetics, considerations for drug use during lactation, and general principles for minimizing risk when drug use is necessary.
This document outlines a marketing plan for Rostin, a new rosuvastatin tablet being launched by South Asian Pharmaceuticals Limited. The objectives are to make Rostin a top-selling brand and highest prescribed product. The executive summary discusses the prevalence of cardiovascular disease and the benefits of statin drugs. It introduces Rostin as a new generation statin with an excellent safety profile. The situation analysis covers the target markets of hyperlipidemia, hypercholesterolemia, and coronary heart disease patients. It analyzes the market demographics, needs, trends, size and growth. The SWOT analysis identifies strengths such as positive brand growth, weaknesses like the need for more promotion, and threats from competing stat
The best brand plan any Post Graduate could prepared is here. This covers with all the aspects from competitor analysis to positioning statement to promatograms. This best brand plan can lead to your success in your career.
hi there .. this poerpoint deal with drugs usage in pregnent women .. th pharmacokinetics .. drug effects on the fetus .. FDA category .. with thanks to my collegues mariam and sherin .. wish to be useful .. enjoy:)
This document discusses paediatric pharmacology. It notes that pharmacokinetic and pharmacodynamic processes differ significantly in paediatric patients compared to adults, especially in neonates and infants, due to developmental changes. Absorption, distribution, metabolism and excretion of drugs are often slower in paediatric patients. It also discusses special considerations for drug dosage forms, compliance, and drug use during lactation in paediatric patients. Careful titration of drug dosages is needed due to pharmacological variability between paediatric individuals.
Snapchat allows users to send pictures and short videos to friends with filters that distort faces for fun. Twitter is used daily by the presenter to stay connected with distant friends and family and informed on news and what others are doing. Instagram is less frequently used to share photos for likes and comments, and to see where friends are and what they are doing.
Lupin launches generic hypertension drug Olmesartan Medoxomil tablets in the US market. Olmesartan is an angiotensin receptor blocker used to treat high blood pressure. It works by relaxing blood vessels to allow blood to flow more easily. Lupin received FDA approval to launch generic versions of Daiichi Sankyo's branded hypertension drug Benicar, which had US sales of $681 million in July 2017. The key safety issues reported for Olmesartan are headache, influenza-like symptoms, and dizziness.
- The document provides sales forecasts for Esoz 20, an esomeprazole magnesium tablet, for the first year in quarterly projections. It estimates sales of Rs. 2.5 crore for the year with sales increasing each month and quarter as penetration increases.
- A promotional budget of Rs. 30 lakh is allocated equally across the 4 quarters to market the brand to gastroenterologists, general physicians, surgeons and gynaecologists in metro and class 1/2 cities.
- Key activities include product sampling, branding materials, and print advertisements. Pricing is set at Rs. 15.93 per tablet with a company margin of 60% after trade discounts.
This document outlines a 10 step marketing plan for Aforvir, an affordable antihistamine medication for children. The target market is physicians who treat allergies in children aged 6 months to 5 years. Aforvir will position itself as effective, affordable, and pleasant tasting compared to competitors. Key elements of the marketing plan include an emotional promotional campaign centered on reuniting children with pets, competitive pricing, and regular physician representative visits to promote Aforvir. The overall antihistamine market is valued at $116 million growing at 16% annually, and the goal is for Aforvir to gain a larger share through this marketing strategy.
Introduction to one of best medicine company Glaxo-smith-kline commonly known as GSK. this presentation gives detail introduction about GSK functions and products. Also global strategies which company is using.
This document discusses marketing strategies for the proton pump inhibitor brand Esotid in Bangladesh. It notes that Esotid contains the molecule Esomeprazole, which has greater bioavailability than other PPIs and can maintain intragastric pH above 4 for over 17 hours. The document encourages promoting Esotid for gastroesophageal reflux disease (GERD) and gastroesophageal reflux-induced chronic cough (GERC), highlighting clinical trial results showing Esomeprazole's superiority to Omeprazole for recovering GERC patients. Promotional materials and messaging are provided to establish Esotid injection in hospitals and inform doctors of Esotid's benefits over other PPI brands for NSAID-
This document discusses strategies for launching new pharmaceutical brands. It outlines that successful product launching depends on coordination across functions. The purpose is to build sales. A launching strategy consists of marketing decisions, activities, and product attributes to present the product to its target market. The objectives are to generate income. Key aspects of launching strategy include being first to market, a first follower, or delayed entrant. Marketing decisions include market entry strategy, product positioning, and marketing mix. Strategic decisions involve company strategy, product strategy, market strategy, and competitive strategy. Tactical decisions involve the marketing mix of product, price, promotion, and distribution. Success depends on customer performance, financial performance, and technical performance. The document provides details on various strategic
Business plan of diclofenac & amoxiclavPallavi Rane
Company X plans to market Diclofenac Potassium and Amoxiclav drugs in Maharashtra and Gujarat. They will have a head office in Mumbai and employ 80 medical representatives to market the drugs. Diclofenac is used for pain and inflammation while Amoxiclav is an antibiotic. The company expects to generate Rs. 72 crore in profits in the first year from drug sales, despite expenses of Rs. 66.54 crore which include salaries, marketing costs, and incentives for medical representatives and doctors.
Nimalox is a non steroidal anti inflammatory drug with
analgesic and antipyretic properties and cox-2
selective inhibition
it's a study to re-branding Nimalox
MBA Cairo University
This document discusses special considerations for drug use in children, the elderly, and patients with hepatic or renal diseases.
In children, drug absorption, distribution, metabolism and elimination can be affected. Formulas like Young's and Clark's are used to calculate appropriate pediatric doses. The elderly have altered pharmacokinetics including slower absorption, lower protein binding, and decreased liver and kidney function. They are also more prone to drug interactions and adverse reactions. Hepatic disease can impact drug metabolism and protein synthesis, requiring dose adjustments. Renal disease reduces drug clearance, increases toxicity risk of nephrotoxic drugs, and may require modified maintenance doses based on creatinine clearance. Special monitoring is needed for safe drug use in these patient
This document discusses strategies for launching new products. It covers several key points:
1. Successful product launching depends on coordination across functions and preparation.
2. Strategic decisions for launching include identifying customers, product positioning, and developing an appropriate marketing mix.
3. Tactical decisions involve the "4 Ps" of marketing - product, price, place (distribution), and promotion.
4. The document provides an overview of different product life cycle stages and strategies for each stage.
Brand plan for 2010 glycomet (us vitamin) - mitesh shahMitesh Shah
The document provides a brand plan for Glycomet, a diabetes medication, for the year 2010. It was prepared by Mitesh Shah and submitted to Mr. Pratim Vora. The plan outlines sales objectives to increase annual unit sales and revenue. It discusses strategies and tactics to achieve these objectives, including effective promotional activities, product design, pricing, and a situational analysis. It also includes a SWOT analysis and details on hiring and training sales personnel to support the outlined goals.
This document outlines the business plan for Losartan Potassium (LOSART) for 2015. It summarizes that hypertension prevalence in Bangladesh is approximately 20% according to different sources. The cardiovascular drug market is valued at 988 crores with antihypertensives comprising 636 crores. LOSART has a 29.24% share of the antihypertensive market as the second most prescribed generic. The plan identifies opportunities to increase market share by focusing on specialty physicians and improving performance in metro areas. Objectives for 2015 include achieving 10% growth, a 4.9% market share, and reaching the number 3 market position.
This document outlines a 10 step marketing plan for Zykast, a new antihistamine/antiallergic drug intended for doctors treating patients over 15 with allergy and asthma symptoms. The plan targets these doctors and analyzes the market, competitors, promotional strategies, and positioning of Zykast to fulfill an unmet need for an affordable, effective treatment with minimal side effects. Key competitors and differentiators are identified. The overall market is estimated at $11.9 billion growing 3% annually.
This document discusses drug use during pregnancy and lactation. It notes that drug use requires special consideration as it affects both the mother and child. Many pregnant or lactating women take drugs for acute or chronic conditions. The document provides details on common drug classes used in pregnancy, considerations for drug safety and effects during each trimester, placental drug transfer, effects of pregnancy on pharmacokinetics, considerations for drug use during lactation, and general principles for minimizing risk when drug use is necessary.
This document outlines a marketing plan for Rostin, a new rosuvastatin tablet being launched by South Asian Pharmaceuticals Limited. The objectives are to make Rostin a top-selling brand and highest prescribed product. The executive summary discusses the prevalence of cardiovascular disease and the benefits of statin drugs. It introduces Rostin as a new generation statin with an excellent safety profile. The situation analysis covers the target markets of hyperlipidemia, hypercholesterolemia, and coronary heart disease patients. It analyzes the market demographics, needs, trends, size and growth. The SWOT analysis identifies strengths such as positive brand growth, weaknesses like the need for more promotion, and threats from competing stat
The best brand plan any Post Graduate could prepared is here. This covers with all the aspects from competitor analysis to positioning statement to promatograms. This best brand plan can lead to your success in your career.
hi there .. this poerpoint deal with drugs usage in pregnent women .. th pharmacokinetics .. drug effects on the fetus .. FDA category .. with thanks to my collegues mariam and sherin .. wish to be useful .. enjoy:)
This document discusses paediatric pharmacology. It notes that pharmacokinetic and pharmacodynamic processes differ significantly in paediatric patients compared to adults, especially in neonates and infants, due to developmental changes. Absorption, distribution, metabolism and excretion of drugs are often slower in paediatric patients. It also discusses special considerations for drug dosage forms, compliance, and drug use during lactation in paediatric patients. Careful titration of drug dosages is needed due to pharmacological variability between paediatric individuals.
Snapchat allows users to send pictures and short videos to friends with filters that distort faces for fun. Twitter is used daily by the presenter to stay connected with distant friends and family and informed on news and what others are doing. Instagram is less frequently used to share photos for likes and comments, and to see where friends are and what they are doing.
The Direct Inmate Supervision (DIS) program at the Clark County Detention Center aims to rehabilitate inmates through various programs. The DIS program operates modules that treat inmates with respect, provide skills training, and encourage good behavior. Classes address topics like parenting, job skills, education, and substance abuse to help inmates successfully reintegrate into society. The goal is to lower recidivism and strengthen families by helping inmates become role models. Inmates in the DIS program reported that it gives them hope and skills to change their lives for the better.
Neelesh Thakare has over 20 years of experience as a Programme Director and Programme Manager, delivering complex ERP programmes globally. He has a track record of successfully managing multi-million dollar budgets and building high-performing teams. Thakare is currently seeking a position leading large-scale transformation programmes using technologies like SAP, Google, and IBM.
MFS (Manchester Furniture Supplies) is the leading furniture dropshipper, manufacturer, wholesaler and sourcing company. Start your own furniture business or add a wide range of modern contemporary high gloss furniture to your existing business. Checkout our new line of contemporary furniture 2016.
-- Created using PowToon -- Free sign up at http://www.powtoon.com/ -- Create animated videos and animated presentations for free. PowToon is a free tool that allows you to develop cool animated clips and animated presentations for your website, office meeting, sales pitch, nonprofit fundraiser, product launch, video resume, or anything else you could use an animated explainer video. PowToon's animation templates help you create animated presentations and animated explainer videos from scratch. Anyone can produce awesome animations quickly with PowToon, without the cost or hassle other professional animation services require.
This unofficial transcript summarizes Michael Balagtas's academic record at California State University Long Beach. He earned a Bachelor of Science degree in Electrical Engineering in 2016. The transcript lists the courses he completed, including general education requirements and honors courses. It shows that he maintained good academic standing and earned academic honors such as the President's List and Dean's List.
- The document provides information on ReNeual, a company developing a portable dialysis machine called DIALO-mini.
- It outlines ReNeual's team members and scientific advisors, as well as its mission to lead renal failure treatment through developing DIALO-mini.
- The document then provides details on DIALO-mini's design, development process, target specifications, growth strategy, and financial projections.
Swati Batra has over 7 years of experience in testing roles. She currently works as a Project Officer for Amdocs in the Netherlands, where her responsibilities include managing project documentation and deliverables, preparing status reports, and coordinating between teams. Previously, she worked as a Senior Testing Engineer for Amdocs in India, where she designed test cases, executed tests, and coordinated with clients on multiple telecom projects. She also has experience as a Software Test Engineer from her time at Damco Solutions.
A Beginners Guide to Homeschool Administration - FPEA 2016Katie Hornor
Beginning to homeschool for the first time can be overwhelming. In this session Katie will explain the nuts and bolts of what you need to do and what you need to keep records of both to stay legal, and to stay sane.
The document discusses learning styles and their importance in education. It identifies the four basic learning styles as visual, auditory, verbal, and kinesthetic. Three secondary styles are also described: logical/mathematical, social, and solitary. Understanding a child's learning style helps educators choose the best curriculum and activities to match how they learn. Recognizing different styles also helps children understand how others process information.
The document provides an overview of the history and development of the global pharmaceutical industry. It discusses key points such as the origin of early pharmacies in Baghdad in 754 AD, the growth of major pharmaceutical companies in the late 19th/early 20th centuries, and key drug discoveries and regulations in subsequent decades. It also summarizes India's large and growing pharmaceutical industry, including top companies, industry structure, government initiatives, and factors influencing future growth.
Pfizer Inc. is the world's largest pharmaceutical company with global operations in over 79 locations. The company applies science and resources to develop therapies that improve lives. Pfizer divides its business into innovative pharmaceuticals, vaccines and consumer healthcare. Key products include Prevnar/Prevenar 13, Lyrica, and Viagra. While facing competition from generic drugs and facing high barriers to entry, Pfizer maintains a leading market position through a diverse portfolio and strong brand recognition.
Pfizer will acquire Hospira for approximately $17 billion in an all-cash deal. The acquisition will enhance Pfizer's global established pharmaceutical business by adding Hospira's injectable drugs and biosimilars portfolio. The combination is expected to generate annual cost savings of $800 million by 2018 and be immediately accretive to Pfizer's earnings per share. The acquisition is subject to regulatory approvals and Hospira shareholder approval.
This curriculum vitae summarizes the career of Dr. Lance K. Gordon, including his extensive experience in vaccine development and leadership of biotechnology companies. He has held roles such as Director of Neglected Infectious Diseases at the Bill & Melinda Gates Foundation, President and CEO of multiple vaccine companies, and clinical roles earlier in his career. Dr. Gordon has overseen numerous vaccine development programs and clinical trials, with a focus on infectious diseases affecting developing countries.
This document provides an overview of a panel discussion on innovative financing trends for European biotechs. The panel will discuss whether EU investors will increase their appetite for risk capital, alternative fundraising options for European companies to achieve more reasonable valuations, and if European companies should seek investment from US markets instead. While European biotech research is strong, US capital markets continue to offer European companies higher valuations, larger investments, and more liquidity compared to domestic exchanges. The panel aims to explore solutions to these regional challenges facing European drug innovators.
HealthXL is the global clearing house for innovation in healthcare. We catalyse collaboration between leading brands in healthcare and the most exciting tech companies to improve the lives of millions of people.
Together with our partners we establish audacious goals (Moonshots) to work towards within healthcare. Then we search for innovators in digital health that can work with us and our partners to achieve those Moonshots. We help them find each other, create business partnerships and facilitate their relationship through collaboration.
Our partners are Bupa, Cleveland Clinic, Becton Dickinson, IBM, ICON, ResMed, Janssen Healthcare Innovation, Linde Healthcare, Novartis, Partners HealthCare, Silicon Valley Bank, EY, SoftServe, and Hermitage Medical Clinic.
This project comprises market overview of one of the leading pharmaceutical manufacturing company Pfizer. It consists company's historical background, Market status, Major critics faced by them. which is helpful for MBA & Marketing students and for further share holders looking up for companies outline. Prepared and submitted on October 2021
The document provides an overview of the pharmaceutical industry in India. It discusses that India has emerged as a major player in the global pharma industry, ranking 3rd in volume and 10th in value. The country exports generic drugs and has become an important destination for contract research and manufacturing. The industry is expected to grow significantly, with sales projected to reach $74 billion by 2020. Key strengths that will support this growth include a large talent pool with skills in areas like R&D, manufacturing according to international standards at low costs, and a favorable regulatory environment. However, increased competition and a stringent regulatory environment also pose threats.
This document provides a comprehensive curriculum vitae and background for Dr. Roy Dittman, an integrative medicine doctor with over 25 years of clinical experience. It outlines his educational background and degrees in Oriental Medicine, post-doctoral certifications, humanitarian work, international travels studying various medical disciplines, and professional experience founding medical clinics and biotech companies. The document also provides details on Dr. Dittman's personal, family, and humanitarian background.
Probiotics and prebiotics nrgastro.2014.66Elsa von Licy
The document presents the conclusions of an expert panel convened by the International Scientific Association for Probiotics and Prebiotics (ISAPP) to discuss definitions and appropriate use of the term "probiotic".
The panel reaffirmed the FAO/WHO definition of probiotics as "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host". The panel clarified inconsistencies between previous FAO/WHO reports and advanced the definition to account for scientific progress.
The panel concluded that certain health effects, such as supporting a healthy digestive tract and gut microbiota, can be reasonably expected from probiotic genera including Bifidobacterium and Lactobacillus. However
15 Influential Women in Cell and Gene Therapy Michael Adeniya
This document discusses several influential women in the cell and gene therapy field and their accomplishments. It begins by introducing Sandra Glucksmann of Editas Medicine and her career advancing gene editing research. It then discusses several other pioneering women, including Yael Margolin of Gamida Cell, Claudia Zylberberg of Akron Biotech, Connie Eaves of BC Cancer Agency, Fiona Watt, Janet Rossant, Helen Martin of Adaptimmune, Katherine High of Spark Therapeutics, Linda Marban of Capricor, Kim Warren, Linda Powers of NorthWest Biotherapeutics, Molly Shoichet, and Sue Washer of AGTC. The document emphasizes that gender diversity leads to more
Brochure (1) 10th Annual World Stem Cells & Regenerative Medicine Congress Ma...John Redaelli
The Stem Cells 2015 conference will take place from 20-22 May in London, featuring keynote speakers from industry leaders, biotech roundtables, and panels from stem cell foundations. Over 500 meetings are expected among 50+ exhibitors and 60+ speakers discussing commercializing cell therapies and gaining market access. Topics will include innovations in regenerative medicine, manufacturing, and new clinical applications for conditions like diabetes and stroke.
6. Analysed the core values, mission and vision statement, resources and capabilities,
stakeholder analysis and engagement, organisation culture of Pfizer. This project report explains the current status of Pfizer in Ireland and future business strategy for business growth. By analyzing PESTEL and SWOT, the report provides a recommendation for the future business strategy for Pfizer to reduce weaknesses in the market.
This document provides an overview of Merck and its recalled drug Vioxx. It discusses Merck's history, leadership, stakeholders, vision, relationship with the FDA, political contributions, use of the blockbuster drug model, direct-to-consumer advertising, Vioxx's rise to fame, emerging safety concerns, and ultimate recall from the market in 2004. The recall came after studies showed Vioxx significantly increased heart attack risks. Questions remain about whether further action should have been taken against those responsible for the deaths and damages caused to consumers by Vioxx.
This case study analyzes the evolution of sustainability efforts at Baxter International Inc. over several decades. It describes how Baxter's formal environmental initiatives began in the 1970s and intensified after an acquisition in the 1990s. In the 2000s, Baxter created an executive sustainability committee and accelerated integration of sustainability across the organization. As a result of its efforts, Baxter has received numerous awards for sustainability performance and reporting. The case study outlines Baxter's history and the methodology used to analyze its progress toward sustainability.
Jeffrey C. Bauer is an internationally recognized health futurist and medical economist based in Chicago. As an independent industry thought leader, he forecasts trends in health care and develops approaches to improve the medical sector. He has over 250 publications on health care delivery and speaks frequently on key trends in health care, medical science, technology, and health reform. Dr. Bauer previously served as Vice President for Health Care Forecasting and Strategy for ACS and founded his own consulting firm. He received his Ph.D. in economics from the University of Colorado-Boulder.
This document provides a business report on Pfizer Inc. prepared by Aileen Marshall. It includes an executive summary analyzing Pfizer's position in the pharmaceutical market. It then gives a company snapshot of Pfizer, including key facts, products, acquisitions and financial performance. Finally, it begins an analysis of Pfizer's current position using a PEST analysis and SWOT analysis to examine political, economic, social, technical, strengths, weaknesses, opportunities and threats facing the company.
Perpective Management- Pharmaceutical Industry Overviewsdusane1
Perception" is defined as the "process by which individuals select, organize, and interpret the input from their senses to give meaning and order to the world around them".[3] Components of perception include the perceiver, target of perception, and the situation. The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications.[1] Pharmaceutical companies may deal in generic or brand medications and medical devices. They are subject to a variety of laws and regulations that govern the patenting, testing, safety, efficacy and marketing of drugs.
Similar to Introduction of Pfizer and it's best sell product-Lipitor (20)
3. Introduction
Pfizer Inc:
an American multinational pharmaceutical corporation;
headquarters in New York City, New York;
area served covering worldwide;
one of the world's largest pharmaceutical companies by revenues;
a world’s premier biopharmaceutical company, based on research;
research headquarters in Groton, Connecticut.
https://en.wikipedia.org/wiki/Pfizer
5. History
In 1849, German-American cousins Charles Pfizer and Charles
Erhart founded Charles Pfizer & Company as a fine-chemicals
business in Brooklyn, NY;
The Civil War pushed the promotion of Pfizer, because of increasing
demand for painkillers, preservatives and disinfectants soars;
In 1868, Pfizer's original administrative headquarters moved to 81
Maiden Lane in Manhattan;
After the Civil War, Pfizer soon became a leader in the American
chemical business and its major product was citric acid;
http://www.pfizer.com/about/history/1849-1899
6. History
During World War II, Pfizer expanded quickly by the reason that
Pfizer alone used fermentation technology to pursue mass
production of penicillin;
In 1950, Pfizer's discovery and commercialization of Terramycin
transformed the company from a manufacturer of fine chemicals to a
research-based pharmaceutical company;
In 1951, in a major international expansion, Pfizer operations were
established in Belgium, Brazil, Canada, Cuba, England, Mexico, Panama,
and Puerto Rico;
During the 1980s and 1990s, Pfizer Corporation growth was
sustained by the discovery and marketing of Zoloft, Lipitor, Viagra
and so on.
http://www.pfizer.com/about/history/1951-1999 & https://en.wikipedia.org/wiki/Pfizer
7. History
Since 2000, Pfizer has grown by merger, including those with
Warner–Lambert (2000) and Pharmacia (2003);
In 2009, Pfizer bought pharmaceuticals rival Wyeth for a combined
$68 billion, and acquired King Pharmaceuticals for $3.6 billion in
2010;
On February 1st 2013, Zoetis, a subsidiary of Pfizer, spun off and
its IPO sold 86.1 million shares for US$ 2.2 billion;
In February 2015, Pfizer and Hospira agreed that Pfizer would
acquire Hospira for $15.2 billion.
https://en.wikipedia.org/wiki/Pfizer & http://dealbook.nytimes.com/2015/02/05/pfizer-to-buy-hospira-a-drug-maker-for-15-2-billion-in-cash/
9. Responsibility
U.S. Patient Assistance Program
help eligible patients get access to their Pfizer medicines;
offer a range of support services, including insurance counseling,
co-pay help, providing Pfizer medicines for free or at a savings, and
more;
be provided through Pfizer RxPathways™, a joint program of Pfizer
Inc and the Pfizer Patient Assistance Foundation™;
from 2010-2014, helped nearly 2.5 million patients in need get
access to over 31 million Pfizer prescriptions, valued at more than
$7.9 billion;
last more than 25 years.
http://www.pfizer.com/responsibility
10. Board of Directors
W. Don Cornwell
Age: 67
Founder and Retired Chairman and CEO
Granite Broadcasting Corporation
Joseph J. Echevarria
Age: 58
Retired CEO
Deloitte LLP
Dennis A. Ausiello M.D.
Age: 70
Director
Center for Assessment Technology and Continuous Health (CATCH)
Frances D. Fergusson Ph.D.
Age: 71
President Emeritus
Vassar College
http://www.pfizer.com/about/leadership_and_structure/meet_board
11. Board of Directors
Helen H. Hobbs M.D.
Age: 63
Investigator
Howard Hughes Medical Institute
James M. Kilts
Age: 67
Founding Partner
Centerview Capital
Shantanu Narayen
Age: 52
President and CEO
Adobe Systems Inc
Suzanne Nora Johnson
Age: 58
Retired Vice Chairman
The Goldman Sachs Group, Inc
http://www.pfizer.com/about/leadership_and_structure/meet_board
12. Board of Directors
Stephen W. Sanger
Age: 69
Retired Chairman and CEO
General Mills
ames C. Smith
Age: 56
President and CEO
Thomson Reuters Corporation
Ian C. Read
Age: 62
Chairman and CEO
Pfizer
http://www.pfizer.com/about/leadership_and_structure/meet_board
13. CEO
Chairman of the Board & CEO
Also is Chairman of the Board of PhRMA and serves on the
Boards of Kimberly-Clark and the Partnership for New York
City;
Was born in Scotland in 1953, and then grew up in Rhodesia
(now Zimbabwe) ;
Received B.Sc. in chemical engineering from London
University Imperial College in 1974 ;
Earned Chartered Accountants certification from the Institute
of Chartered Accountants of England and Wales in 1978 ;
Ian C. Read
Age: 62
http://www.pfizer.com/about/leadership_and_structure/leadership_executives/ian_c__read
14. CEO
From 1978, worked for Pfizer as an operational auditor;
Through 1995, worked in Latin America, holding positions from CFO
of Pfizer Mexico to Country Manager of Pfizer Brazil, and in 1996, was
appointed President of Pfizer's International Pharmaceuticals Group,
with responsibility for Latin America and Canada;
In 2000, was appointed Executive Vice President of Europe; in 2001,
was named a Corporate Vice President and assumed responsibility
for Canada; in 2002, became accountable for operations in both the
Africa/Middle East region and Latin America as well;
From 2006 to 2010, led the Pfizer Worldwide Biopharmaceutical
Businesses, as Senior Vice President;
On December 5 2010, became CEO of Pfizer.
Ian C. Read
Age: 62
http://www.pfizer.com/about/leadership_and_structure/leadership_executives/ian_c__read
15. CFO
Frank D'Amelio
Age:57
EVP, Business Operations & CFO
Received Bachelor’s degree in Accounting from St. Peter’s
College;
Earned MBA in Finance from St. John’s University;
From 1979 to 2007, Worked for Bell Laboratories, AT&T and
Lucent, holding a variety of financial, accounting and general
management positions;
In September 2007, started to worked for Pfizer, and in December
2010, was appointed as CFO;
In 2005, 2006, 2011, 2012 and 2013, was ranked among
America’s top CFOs by Institutional Investor magazine.
http://www.pfizer.com/about/leadership_and_structure/leadership_executives/frank_d_amelio
16. Mikael Dolsten
President of Worldwide Research and Development & EVP
Earned his Ph.D. in tumor immunology and M.D. from the
University of Lund in Sweden in 1988;
Studied virology and cell biology at the Weizmann Institute in Israel
and has been appointed as Adjunct Professor in Immunology at
the Medical Faculty in Lund;
From June 2008 to October 2009, Senior vice president of Wyeth
and President of Wyeth Research;
In 2009, joined Pfizer and in December 2010, was appointed
President of Worldwide Research and Development;
Has several patents and published approximately 150 articles in
international journals.
http://www.pfizer.com/about/leadership_and_structure/leadership_executives/mikael_dolsten_m_d_ph_d_
President of Research
17. Other NEOs
Geno Germano
Group President, Global Innovative Pharma Business
Joined Pfizer from Wyeth Pharmaceutica;
With more than 25 years of international experience in the
pharmaceutical industry, held many positions including Executive Vice
President and General Manager
John Young
Group President, Global Established Pharma Business
Earned Bachelor of Science degree in Biology from Glasgow University
and an MBA from Strathclyde Graduate Business School;
Joined Pfizer in 1987, led Pfizer’s global Primary Care organization,
prior to assuming leadership of the Global Established Pharma business.
http://www.pfizer.com/about/leadership_and_structure/leadership_executives/geno_germano &
http://www.pfizer.com/about/leadership_and_structure/leadership_executives/john_young
22. Products
Lipitor was the world's top-selling drug from 1996 to 2012.
Over 14.5 years, it has made over $125 billion in sales, and has
provided up to a quarter of Pfizer Inc.'s annual revenue for years.
http://www.crainsnewyork.com/article/20111228/HEALTH_CARE/111229902
LIPITOR
lipid toro
Atorvastatin
25. The Story
• Akira Endo Is a Japanese Biochemist.
• His research into the relationship
between fungi and cholesterol biosynthesis
led to the discovery of statin drugs in 1971.
• He was awarded the 22nd Japan Prize in 2006
and the Lasker Award in 2008.
oyster mushroom Aspergillus terreus
Red Yeast Rice
Endo, Akira (2004). "The origin of the statins". International Congress Series 1262: 3–8.
http://www.scienceheroes.com/index.php?option=com_content&view=article&id=126&Itemid=135
26. Cholesterol Regulation Metabolism
• The 1985 Nobel Prize in Physiology or Medicine was awarded to Michael S. Brown and
Joseph L. Goldstein, “for their discoveries concerning the regulation of cholesterol
metabolism.” Their work on HMGR and LDL elucidated the regulatory complexity of
cholesterol synthesis.
http://www.nobelprize.org/nobel_prizes/medicine/laureates/1985/
27. Lipitor (Atorvastatin)
Achievements
• In 1985 Atorvastatin was invented by Bruce Roth.
• He synthesized a chiral side chain similar to HMG-CoA
reductase binding substrate.
• 1981 Ph.D in Organic Chemistry form Iowa State University.
• 1982 Medicinal Chemist at Warner Lambert Company.
• 2000 Vice president of chemistry at pfizer.
• 2007 Vice president of Discovery Chemistry at Genentech.
Awards
• 1997 Warner Lambert Distinguished Scientific Achievement
Award.
• 1999 Inventor of the Year Award by NYIP Law Association.
• 2003 Creative Invention award and on 2008 Hero of
Chemistry by American Chemical Society.
http://www.chemheritage.org/about/news-and-press/press-releases/2013-05-30-bruce-roth-to-receive-2013-sci-perkin-medal.aspx
28. Lipitor (Atorvastatin)
• Member of drug class Statins.
• Completely synthetic drug.
• It inhibits 3- hydroxy-3-
methylglutaryl-coenzyme A (HMG-
CoA) reductase, found in liver.
• It effect was more spectacular in
reducing LDL levels than any of the
other statins drugs.
• The major medical use of
Atorvastatin is to treat dyslipidemia
which can lead to Atherosclerosis
and other cardiovascular and non-
cardiovascular diseases.
Atorvastatin
Adams, S. P., Tsang, M., & Wright, J. M. (2015). Lipid lowering efficacy of atorvastatin. The Cochrane Library.
29. Lipoproteins
High Density Lipoproteins (HDL)- GOOD
Low Density Lipoproteins (LDL) BAD
Coronary Heart Disease and other
cardiovascular diseases
World Leading Cause of Death
Cholesterol & Lipoproteins
• Cholesterol is a very significant
Biological Molecule. (Ex: Cell
membrane, Vitamin D and
precursor of steroid Hormones).
• Cholesterol is biosynthesized
internally, not dietary.
• Lipoproteins are molecule made
of proteins and fat.
• Cholesterol use lipoproteins to
bind to and move within
vascular system.
Cholesterol
Cox RA, García-Palmieri MR. Cholesterol, Triglycerides, and Associated Lipoproteins. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical
, and Laboratory Examinations. 3rd edition. Boston: Butterworths; 1990. Chapter 31. Available from: http://www.ncbi.nlm.nih.gov/books/NBK351/
33. Atherosclerosis New Prospective
Complex interactions:
• Vascular Endothelial Cells.
• Inflammatory Leukocyte.
• Cholesterol Transporting Lipoproteins.
• Cardiovascular Risk Factors.
Peter Libby, MD; Paul M. Ridker, MD; Attilio Maseri, MD. Inflammation and Atherosclerosis. American Heart Association
34. Thrombosis
Acute coronary syndrome and stroke
Causes the most dramatic clinical consequences of atherosclerosis
Peter Libby, MD; Paul M. Ridker, MD; Attilio Maseri, MD. Inflammation and Atherosclerosis. American Heart Association
35. Atherosclerosis & Lipoproteins
• Imbalance in plasma
lipoproteins contribute
importantly in atherosclerosis.
• High LDL
• High triglyceride lipoproteins
VLDL- Very Low Density
Lipoproteins.
IDL- Intermediate Density
Lipoproteins.
• Low HDL
• Will increase the risks of
atherosclerosis.
http://www.ncbi.nlm.nih.gov/pubmed/3330421
36. • All cells require cholesterol & lipoproteins
• Lipoproteins normally package cholesterol (insoluble molecule) in a
form redly transported in the blood.
• Factors such as unhealthy diet or genetic disposition over low this
essential lipid transport pathway and contribute to dyslipidemia
that promote atherosclerosis disease
Cholesterol & Lipoproteins
Peter Libby, MD; Paul M. Ridker, MD; Attilio Maseri, MD. Inflammation and Atherosclerosis. American Heart Association
37. Body Management of Cholesterol
• Begins in the liver.
• High LDL can results from:
1. Excessive production of triglyceride rich VLDL.
2. Inadequate uptake of LDL by liver and peripheral cells due to low numbers of or
genetic defect in LDL receptors.
http://www.ncbi.nlm.nih.gov/pubmed/3330421
38. Cholesterol Biosynthesis
• Synthesis of cholesterol begins
in the cytosol.
• Thee molecules of Acetyl-Co
Enzyme A interact to form 3-
hydroxy-3-methylglutaryl-
coenzyme A (HMG- CoA).
• HMG-Coa then react with
HMG-CoA reductase (an
enzyme that reside in the
membrane of the smooth
endoplasmic reticulum.
Rate
Limiting
Step Smooth
Endoplasmic
Reticulum
The Coenzyme (substrate)
HMG-CoA reductase
(enzyme)
https://www.rpi.edu/dept/bcbp/molbiochem/MBWeb/mb2/part1/cholesterol.htm
39. HMG- CoA Reductase
• Tetrameric macro-molecule.
• Active site is deep within each
monomer.
• Four binding sites one within
each monomer.
Cholesterol Biosynthesis
https://www.rpi.edu/dept/bcbp/molbiochem/MBWeb/mb2/part1/cholesterol.htm
40. • HMG- CoA Reductase using
NADPH catalysis the reduction
of HMG-CoA to Mevalonate
• Mevalonate undergoes several
subsequent transformation to
form other steroid precursor,
and ultimately cholesterol.
Cholesterol Biosynthesis
Rate
Limiting
Step
https://www.rpi.edu/dept/bcbp/molbiochem/MBWeb/mb2/part1/cholesterol.htm
https://www2.chemistry.msu.edu/Courses/CEM958/FS06_SS07/Amand.pdf
41. Statins
Statins by inhibiting cholesterol
synthesis in the liver can:
• lower LDL levels
• Improve the overall lipoproteins
profile
• Significantly reduce clinical
cardiovascular events in several ways.
42. Statin Inhibition
HMG- CoA Reductase binding site, with
statin partially bind to it.
• Statin competitively bind the
active site of HMG-CoA
reducatase.
• Statin inhibits the conversion
of HMG-CoA to Mevalonate.
• Therefore it alter the pathway
that leads to cholesterol.
Lipitor
Lipitor
Gaw A, Packard CJ, Shepherd J. Statins: The HMG CoA Reductase Inhibitors in Perspective. London, England: Martin Dunitz Ltd, 2000. [: ISBN
43. What Can Cause AtherosclerosisStatin Inhibition Binding HMG- CoA Reductase
Polar interactions are formed between the HMG-moiety and residues that are
located in the cis loop of the enzyme. These polar interactions are between
Ser684, Asp690, Lys691 and Lys692
Rosuvastatin
• Statin enter a narrow binding
pocket and form 8 to 12
binding interaction with
hydrophobic moieties lining
the pocket
• Pockets undergoes
conformational change
• Actual molecular details of
statin binding to the active
site
stvan, Eva S.; Deisenhofer, Johann (May 2001). "Structural Mechanism for Statin Inhibition of HMG-CoA Reductase". Science Magazine 292
44. Statins
Gaw A, Packard CJ, Shepherd J. Statins: The HMG CoA Reductase Inhibitors in Perspective. London, England: Martin Dunitz Ltd, 2000. [: ISBN
45. Statins
Gaw A, Packard CJ, Shepherd J. Statins: The HMG CoA Reductase Inhibitors in Perspective. London, England: Martin Dunitz Ltd, 2000. [: ISBN
46. Statins
Gaw A, Packard CJ, Shepherd J. Statins: The HMG CoA Reductase Inhibitors in Perspective. London, England: Martin Dunitz Ltd, 2000. [: ISBN
47. Feedback by SREBPs
• Statin therapy inhibits intercellular
cholesterol synthesis, causing
cholesterol levels in the cell to fall.
• Changes in cholesterol levels
triggers sensing mechanisms.
• These sensing mechanisms are
proteins bound to intercellular
membranes called sterol regulatory
elements binding proteins SREBPs.
• In particular activation of SREBPs by
low cholesterol, increase
transcription of the LDL receptor
gene.
• The consequent rise in LDL receptor
number, promotes capture of LDL &
VLDL from the blood to maintain
cellular cholesterol homeostasis
Low
cholesterol
levels
Signal
SREBPs
Activate LDL
receptor
transcription
http://www.utsouthwestern.edu/labs/beutler/research/new-genes.html
48. Feedback by SREBPs
• SREBPs also:
increase the synthesis of HMG- CoA reductase.
Reduce cellular pools of cholesterol.
slow the rate of VLDL production.
• Statin therapy can therefore lower blood VLDL levels, as a result,
levels of HDL may rise because of reduced transfer of cholesterol
ester from HDL to VLDL by cholesterol ester transfer protein.
http://www.utsouthwestern.edu/labs/beutler/research/new-genes.htmlhttp://www.utsouthwestern.edu/labs/beutler/research/new-genes.html
51. Why Lipitor
Comparing Different pharmacological Statins properties
Vaughan, Carl J.; Gotto, Jr., Antonio M. (June 2004). "Update on Statins: 2003". Circulation, Journal of the American heart association 110
52. Future Research
In this study three-dimensional quantitative structure−activity relationship (3D QSAR) with comparative
molecular field analysis (CoMFA) was performed on a training set of up to 35 statins and statin-like
compounds. Predictive models were established by using two different ways: (1) Models-fit
Qing Y. Zhang,†, Jian Wan,*,†, Xin Xu,*,‡, Guang F. Yang,†, Yan L. Ren,†, Jun J. Liu,†, Hui Wang,§ and, and Yu Guo§. Structure-Based Rational Quest for
Potential Novel Inhibitors of Human HMG-CoA Reductase by Combining CoMFA 3D QSAR Modeling and Virtual Screening. Journal of Combinatorial Chemistry 2007
53. Patient Information
Indication & Usage
• Prevention of Cardiovascular Disease
• Hyperlipidemia.
• Lipitor has not been studied in conditions
where the major lipoprotein abnormality is
elevation of chylomicrons.
http://www.lipitor.com/ (Patient Information)
http://labeling.pfizer.com/ShowLabeling.aspx?id=587#page=23
54. Patient Information
Administration
• orally, once a day, with or without
food. Take the medicine at the same
time each day.
• Do not break or crush a tablet before
taking it.
• Avoid foods that are high in fat or
cholesterol, alcohol, and grapefruit
and grapefruit juice.
http://www.lipitor.com/ (Patient Information)
http://labeling.pfizer.com/ShowLabeling.aspx?id=587#page=23
55. Patient Information
Dosage Forms & Strengths
• White.
• Elliptical.
• Film-coated tablets.
• 10, 20, 40, and 80 mg atorvastatin
calcium.
http://www.lipitor.com/ (Patient Information)
http://labeling.pfizer.com/ShowLabeling.aspx?id=587#page=23
56. Patient Information
Contraindications; Caution should be used!
• In patients with active liver disease or with unexplained
elevation of liver function enzyme levels.
• Not safe for women who are pregnant or may become
pregnant.
• Women who require Lipitor Shouldn’t breastfeed infants.
http://www.lipitor.com/ (Patient Information)
http://labeling.pfizer.com/ShowLabeling.aspx?id=587#page=23
58. Patient Information
• Warning & Precautions
• Certain other drugs can increase
your risk of serious muscle
problems, and it is very important
that your doctor knows if you are
using any of them.
• Tell your doctor about all your
current medicines and any you start
or stop using, especially:
Antibiotic or antifungal medicine;
Birth control pills;
Cholesterol-lowering medication;
Heart medication; or
Medicine to treat HIV or AIDS.
http://www.lipitor.com/ (Patient Information)
http://labeling.pfizer.com/ShowLabeling.aspx?id=587#page=23
60. SWOT Analysis
Strength
‧Large pharmaceutical company
‧Excellent research and development
‧Mergers with big pharma brands
‧Strong brand name
Opportunity
‧Strategic agreements
‧Increasing awareness about healthcare
‧Global penetration
‧Increasing demand for healthcare
Weakness
‧Competitors
‧Patents expiration
Threat
‧Risk of unsuccessful new Products
‧Regulatory environment become stringent
‧Economic slowdown in European markets
61. FINANCIAL PERFORMANCE
2014 2013 2012 2011 2010
Revenues 49,605 51,584 54,657 61,035 61,591
Research and
development
expenses
8,393 6,678 7,482 9,074 9,483
Total assets 169,274 172,101 185,798 188,002 195,014
(Millions)
AS OF AND FOR THE YEAR ENDED DECEMBER 31
63. SWOT Analysis
Strength
‧Large pharmaceutical company
‧Excellent research and development
‧Mergers with big pharma brands
‧Over 100,000 employees
‧Strong brand name
Opportunity
‧Strategic agreements
‧Increasing awareness about healthcare
‧Global penetration
‧Increasing demand for healthcare
Weakness
‧Competitors
‧Patents expiration
Threats
‧Risk of unsuccessful new Products
‧Regulatory environment become stringent
‧Economic slowdown in European markets
64. After being a patent-protected monopoly for
14 years on the market…
Here come to an inevitable
challenge…
65. Fight with this challenge
• Pay-for-Delay
• Authorized Generic
• Acquire King Pharmaceuticals
• Lipitor Choice
• Increases Retail Price
• Marketing
• Over-The-Counter Version
66. Pay-for-Delay
• Federal Trade Commission
can delay the launching of generic version by paying
• Hatch-Waxman Act
a 180-day marketing exclusivity period
• Ranbaxy
the first manufacturer approved selling generic Lipitor
67. Pay-for-delay
• Pfizer and Ranbaxy entered into an agreement
in 2008
Ranbaxy: can sell a generic Caduet seven years earlier
Pfizer: get more time for the preparation of new drug
launching.
• Ranbaxy launched the first generic version of
Lipitor on December 1, 2011
http://www.drugsdepot.co
m/catalog.php/drugsdepot/
pg17538
68. Authorized Generic
• What is “Authorized generics”
the prescription drug produced by brand pharmaceutical
company and marketed under a private label, at generic price
• Watson Pharmaceuticals
is a global pharmaceutical company now known for Actavis
69. Authorized Generic
• Authorized generic of Lipitor launching
Watson: can launch an authorized generic of Lipitor at the
same time as Ranbaxy
Pfizer: can take 70 % of its Lipitor-related profits from Watson
http://www.thestar.com/life/health_wellnes
s/2014/10/14/ontario_health_minister_pled
ges_review_of_generic_drug_costs.html
70. Market Share of AtorvastatinMarketShare(%)
http://www.firstpost.com/investing/lipitor-sales-why-ranbaxys-rs-2983-cr-loss-wont-worry-investors-223915.html
71. Acquire King Pharmaceuticals
• Expand the product line of pain relief
On October 12, 2010, Pfizer acquired King Pharmaceuticals
• The most attractive product
Flector Patch
EpiPen
epinephrine autoinjector
emergency delivery of medications
http://medlibrary.org/lib/rx/meds/flec
tor-1/page/4/
http://www.thisweeknews.com/content/sto
ries/dublin/news/2015/10/06/board-
considering-change-to-its-medical-
policies.html
72. Lipitor Choice
• “Lipitor for you” in 2011
• The latest version launched in 2014
• How does LIPITOR Choice work
$4 for a 30-day supply: patients whose insurance plans cover
LIPITOR up to a $130 out-of-pocket cost
$30 for a 30-day supply: patients whose insurance plans do
not cover LIPITOR, or over $130 out-of-pocket cost, uninsured
patients, as well as Medicare Part D patients
https://www.lipitor.com/choice-card
73. Increases Retail Price
More than four times
the average annual
price increase
Rx Price Watch Case Study: Efforts to Reduce the Impact of Generic Competition for Lipitor. AARP Public Policy Institute
74. Marketing
• Pfizer still maintained high levels of marketing
spending before the patent expired.
75. Over-The-Counter Version
• What is “OTC”
sold directly to a consumer without a prescription
• Tried to persuade the FDA to allow it to sell
Lipitor over the counter
• Did they make it?
The study did not meet its primary objectives of
demonstrating patient compliance with the direction to check
their low-density lipoprotein cholesterol (LDL-C) level and,
after checking their LDL-C level, take appropriate action based
on their test results. Based on dialogue with the FDA about
the program and analysis of this data, the program was
terminated.
76. How these strategies works
• Can still keep some market
http://seekingalpha.com/article/1516292-bitter-pill-of-expiring-patents-to-swallow-for-pfizer
77. What is Pfizer going to work on
• Alliances and licensing arrangements
helps Pfizer reduce R&D expenses
• Acquisition with other company
boost growth of Pfizer
• Product pipeline
As of October 27, 2015http://www.pfizer.com/research/science_and_technology/product_pipeline
Cholesterol is a very significant Biological Molecule. (Ex: Cell membrane, and precursor of steroid Hormones)
Cholesterol is biosynthesized internally, not dietary.
They use lipoproteins to bind to and movie within vascular system.
Polar interactions are formed between the HMG-moiety and residues that are located in the cis loop of the enzyme. These polar interactions are between Ser684, Asp690, Lys691 and Lys692